English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

MicroRNAs (miRs) have vital involvement in the advancement of non-small cell lung cancer (NSCLC); however, the methods of action of miR-449b-3p in the disease are yet to be examined. The present study revealed a distinct downregulation of miR-449b-3p in NSCLC tissue, which was related to the clinicopathological characteristics, and may serve as an independent marker for NSCLC prognosis. NSCLC cell epithelial-mesenchymal transition (EMT), metastasis and migration were distinctly controlled in vitro by miR-449b-3p, that was found to directly target interleukin (IL)-6. Additionally, increased IL-6 level could inhibit miR-449b-3p and suppress the effect of EMT in NSCLC cells by inactivating the Janus kinase 2 (JAK2)/STAT3 signaling pathway. In conclusion, the data from the present study demonstrated that IL-6 is targeted by miR-449b-3p, which affects the JAK2/STAT3 signaling pathway, impacting on the development of NSCLC.

experimental and therapeutic medicine

MicroRNA‑449b‑3p inhibits epithelial‑mesenchymal transition by targeting IL‑6 and through the JAK2/STAT3 signaling pathway in non‑small cell lung cancer